Table 2.
Changes in Behavioral Outcomes During and Following Direct-acting Antiviral Treatment for Hepatitis C Virus Infection Among People With Recent Injection Drug Use or Receiving Opioid Agonist Treatment Recruited and Followed in SIMPLIFY and D3FEAT, by Incremental Study Visits
| Variable | Adjusted Odds Ratio (95% Confidence Interval)a,b | P Value |
|---|---|---|
| Injection drug use, past month | .96 (.92–.99) | .02 |
| Opioid injection, past month | .95 (.92–.99) | .01 |
| Stimulant injection, past month | .98 (.94–1.02) | .33 |
| Sharing injection equipment, past month | .87 (.80–.94) | <.01 |
| Alcohol use, past month | .99 (.95–1.04) | .75 |
| Current opioid agonist treatment | .99 (.97–1.02) | .45 |
| Noninjecting opioid use, past month | .96 (.91–1.01) | .16 |
| Noninjecting stimulant use, past month | 1.00 (.97–1.03) | .94 |
aAdjusted for opioid agonist treatment at each visit.
bThe estimated odds ratio indicates the average behavior change across 2 consecutive visits, irrespective of time lapses between visits.